A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

Yiming Cheng,1 Ying Ye,1 Allison Gaudy,1 Atalanta Ghosh,2 Yongjun Xue,3 Alice Wang,1 Simon Zhou,1 Yan Li1 1Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA; 2Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USA; 3Nonclinical Research &...

Full description

Bibliographic Details
Main Authors: Cheng Y, Ye Y, Gaudy A, Ghosh A, Xue Y, Wang A, Zhou S, Li Y
Format: Article
Language:English
Published: Dove Medical Press 2023-02-01
Series:Clinical Pharmacology: Advances and Applications
Subjects:
hepatic impairment
iberdomide
pharmacokinetics
Online Access:https://www.dovepress.com/a-phase-1-multicenter-open-label-study-to-evaluate-the-pharmacokinetic-peer-reviewed-fulltext-article-CPAA

Similar Items

Similar Items